Veterinary biologic

MEDGENE'S RHDV2 VACCINE GRANTED CRITICAL LICENSE BY USDA'S CENTER FOR VETERINARY BIOLOGICS

Retrieved on: 
Thursday, November 2, 2023
Foreign animal disease, Virulence, United States Department of Agriculture, Health, Hope, Emergency Use Authorization, USDA, Rabbit hemorrhagic disease, Death, Vaccination, Disease, Immunity, Animal, Veterinary biologic, House Rabbit Society, Safety, Heart, Vaccine, Livestock

BROOKINGS, S.D., Nov. 2, 2023 /PRNewswire/ -- Medgene, an animal health company that produces highly-targeted platform vaccines, has been granted a Conditional Use License by the United States Department of Agriculture's Center for Veterinary Biologics (USDA-CVB) to further manufacture and distribute its vaccine targeted at Rabbit Hemorrhagic Disease (RHDV2).

Key Points: 
  • BROOKINGS, S.D., Nov. 2, 2023 /PRNewswire/ -- Medgene, an animal health company that produces highly-targeted platform vaccines, has been granted a Conditional Use License by the United States Department of Agriculture's Center for Veterinary Biologics (USDA-CVB) to further manufacture and distribute its vaccine targeted at Rabbit Hemorrhagic Disease (RHDV2).
  • Once contracted, RHDV2 is usually fatal and affects wild and domestic rabbit populations.
  • Medgene's Conditional Use License is especially important for designated State Veterinarians as they are the authority allowing distribution of the vaccine within their respective states.
  • Rabbit owners are encouraged to contact their local veterinarian for more information on RHDV2 and vaccination.

Trial Results Confirm Efficacy of ZIVO Bioscience’s Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens

Retrieved on: 
Tuesday, September 19, 2023
Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Veterinary, Coccidiosis, Human, Bird, Fungal infection, Diarrhea, Poultry, Veterinary biologic, Weight loss, Licensure, Livestock, Research, Incidence, Animal, Mortality, Disease, Vaccine, Poultry farming, Chicken

Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance, and increased mortality in poultry.

Key Points: 
  • Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance, and increased mortality in poultry.
  • Birds treated with ZIVO’s product candidate demonstrated statistically significant improvements across all measures of broiler health examined.
  • Diseased chickens treated with elevated doses of ZIVO's product candidate exhibited reductions in disease-related effects to a level seen in healthy birds.
  • As a result, ZIVO remains confident that its novel product candidate for broiler chickens presents a disruptive solution to coccidiosis, one of the most significant challenges facing the global poultry industry.

HISTORIC MILESTONE IN ANIMAL HEALTH CARE REACHED BY SOUTH DAKOTA VACCINE COMPANY

Retrieved on: 
Monday, June 12, 2023
Vaccine, University, Veterinary biologic, Influenza D virus, Veterinarian, Licensure, Multimedia, Government, CVB, RMIT Platform Technologies Research Institute, Animal, USDA, Health, Iowa State University, DVM, Papillomaviridae, Disease, Coronavirus, Rotavirus

BROOKINGS, S.D., June 12, 2023 /PRNewswire/ -- The USDA Center for Veterinary Biologics (CVB) has allowed animal health company, Medgene, license to produce and market a USDA - approved category of vaccines called Platform Vaccines to the cattle industry. Specific cattle vaccines available under this new Platform Vaccine category include Influenza D, Coronavirus, Rotavirus, and Papillomavirus.

Key Points: 
  • Specific cattle vaccines available under this new Platform Vaccine category include Influenza D, Coronavirus, Rotavirus, and Papillomavirus.
  • - Robert Gentry, DVM
    Medgene's vaccine approaches leverage USDA-approved "platform technology" guidelines that are safe, and easily adapted to multiple animal disease targets.
  • Veterinarian and advocate of Platform Vaccines, Bob Gentry, DVM, stated "For the veterinarian, Platform Technologies improve our option in providing care.
  • From government regulatory to university research to the extraordinary team at Medgene, Platform Vaccines are a historic example of teamwork towards a common goal - improving animal health."

USDA CENTER FOR VETERINARY BIOLOGICS ALLOWS GROUNDBREAKING PLATFORM TECHNOLOGY PORTFOLIO OF VACCINES TO PORK INDUSTRY

Retrieved on: 
Monday, June 12, 2023
Vaccine, National Veterinary Services Laboratory, Veterinary biologic, Veterinarian, Licensure, Food, Multimedia, CVB, Iowa State Fair, USDA, Health, LTD, Safety, Pig, Sapovirus, Platform, Rotavirus

BROOKINGS, S.D., June 12, 2023 /PRNewswire/ -- The USDA Center for Veterinary Biologics (CVB) has allowed animal health company, Medgene, license to produce and market a USDA - approved Platform Vaccine to the pork industry. The license applies to use of their Platform technology to produce vaccines addressing disease targets such as Rotavirus, Porcine Circovirus, Influenza A, and Sapovirus.

Key Points: 
  • BROOKINGS, S.D., June 12, 2023 /PRNewswire/ -- The USDA Center for Veterinary Biologics (CVB) has allowed animal health company, Medgene, license to produce and market a USDA - approved Platform Vaccine to the pork industry.
  • The license applies to use of their Platform technology to produce vaccines addressing disease targets such as Rotavirus, Porcine Circovirus, Influenza A, and Sapovirus.
  • Medgene's vaccine approach leverages a USDA-approved "platform technology" that is safe and easily adapted to multiple animal disease targets.
  • We've been working on getting the power of Platform technology into the hands of pork industry veterinarians for many years.

Torigen Pharmaceuticals and VerticalVet Enter into Preferred Partnership

Retrieved on: 
Thursday, December 8, 2022
Emerald, University of Notre Dame, Dog, PETS, Therapy, GRC, Immune system, Veterinarian, University of Connecticut, Immunotherapy, University, Diagnosis, Automation, Cornelius, North Carolina, Partnership, CFR, Health, Patient, Cornelius, Entrepreneurship, Cancer, Animal, Veterinary biologic, Radiation, Cat, General practitioner, Notre Dame, National Veterinary Services Laboratory, Neoplasm, Parent, Horse, Cell, Growth, Veterinary medicine, Pharmaceutical industry, Medical imaging, Vaccine

FARMINGTON, Conn., Dec. 8, 2022 /PRNewswire-PRWeb/ -- Torigen Pharmaceuticals, Inc (Farmington, CT), an animal health biologics company, announced today that they have entered into a Preferred Partnership Agreement with VerticalVet, LLC(Cornelius, NC) to provide their 2,000+ clinic Group Purchasing Organization with access to Torigen. VerticalVet provides independent veterinary owners, practice managers, and technicians access to customized best practices education, real-time data insights, simplified marketing automation, and tailored partner solutions, such as Torigen's Experimental Autologous Prescription Product.

Key Points: 
  • FARMINGTON, Conn., Dec. 8, 2022 /PRNewswire-PRWeb/ -- Torigen Pharmaceuticals , Inc (Farmington, CT), an animal health biologics company, announced today that they have entered into a Preferred Partnership Agreement with VerticalVet, LLC (Cornelius, NC) to provide their 2,000+ clinic Group Purchasing Organization with access to Torigen.
  • "We are excited to partner with VerticalVet's 2,000 veterinary hospitals nationwide," says Ashley Kalinauskas, CEO and Co-Founder of Torigen Pharmaceuticals.
  • "We are excited to finalize a partnership with Torigen and look forward to supporting their journey and continued success."
  • "Our partnership with Torigen provides VerticalVet members access to individualized cancer therapy that promises to change the way veterinarians treat cancer."

2022 World Rabies Day webinar explores challenges and opportunities for remote Canadian communities tackling rabies

Retrieved on: 
Wednesday, September 28, 2022
World Rabies Day, Health, Risk, Veterinarian, Environment, Rabies, CEO, Vaccine, Public health, Veterinary biologic, GLOBE, PETS, Awareness, Red fox, Animal, First Nations, Dog

Toronto, Ontario, Sept. 28, 2022 (GLOBE NEWSWIRE) -- The Canadian Animal Health Institute (CAHI) is pleased to host the second annual World Rabies Day webinar as a part of World Rabies Day 2022.

Key Points: 
  • Toronto, Ontario, Sept. 28, 2022 (GLOBE NEWSWIRE) -- The Canadian Animal Health Institute (CAHI) is pleased to host the second annual World Rabies Day webinar as a part of World Rabies Day 2022.
  • This World Rabies Day event aims to support the development of both animal health and public health in Canadas remote northern communities by building increased awareness of the challenges and opportunities across Canadas unique geography.
  • Made possible by the generous support of Zoetis Canada Inc. and Boehringer Ingelheim Animal Health Canada Inc., the World Rabies Day 2022 webinar will be hosted by CAHI later today, from 12:00 1:00pm EDT.
  • For webinar information and free registration, see https://live.webcastcanada.ca/go/rabies-english
    Established in 1968, CAHI is the trusted, science-based voice of the Canadian animal health industry.

Dalan Animal Health Closes $3.55 Million Financing Round for Launch of the World’s First Honeybee Vaccine

Retrieved on: 
Tuesday, September 27, 2022
Finance, Pharmaceutical, General Health, Professional Services, Other Natural Resources, Environment, Environmental Health, Venture Capital, Agriculture, Natural Resources, Biotechnology, Science, Veterinary, Other Science, Research, Health, Reproduction, Invertebrate, Health, Agriculture, Genetically modified bacteria, Vaccination, Growth, Version One Ventures, U.S. Department of Defense Strategy for Operating in Cyberspace, Technology, Vaccine, Louisiana State University Agricultural Center, Solution, Seed, Nut, Veterinary biologic, Ecosystem, Food, Biomass, Organic, Plant, Disease, Soil, Aquaculture, American foulbrood

Dalan Animal Health, Inc., a biotech company pioneering insect health and immunology, today announced the close of a $3.55 million seed financing round led by At One Ventures and Veterinary Angel Network for Entrepreneurs (VANE).

Key Points: 
  • Dalan Animal Health, Inc., a biotech company pioneering insect health and immunology, today announced the close of a $3.55 million seed financing round led by At One Ventures and Veterinary Angel Network for Entrepreneurs (VANE).
  • This is the second seed round of funding and the first including institutional investors, bringing the total raise to $5.5 million.
  • The vaccine that Dalan is developing is non-GMO, has no harmful additives, and is suitable for use in organic agriculture.
  • Dalan is not only a bee vaccine company but is pioneering sustainable solutions in insect health to save our planet.

ZIVO Bioscience CEO Issues Letter to Shareholders

Retrieved on: 
Friday, September 23, 2022
Health, Infectious Diseases, Agriculture, Natural Resources, Pharmaceutical, Biotechnology, Veterinary, Securities Exchange Act of 1934, Adoption, Health, Gaps, Incidence, Human, Review, Salmonella, CVB, Poultry, Energy Independence and Security Act of 2007, Chicken, Licensure, Farmer, Acquisition, Growth, Intellectual property, USDA, Immunity, Industry, Clostridium perfringens, Achievement, Securities Act of 1933, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, U.S. Securities and Exchange Commission, Letter, Escherichia coli, Nutrient, CEO, Technology, Vaccine, Goal, Coccidiosis, Board of directors, Leadership, Ill, Agtech, List of life sciences, Veterinary biologic, NASDAQ, Biomass, Board, Research, Security (finance), U.S. Department of Agriculture Cotton Annex, Animal, Immune system, Self-affirmation, Disease, Livestock, Management, Fine chemical, Aquaculture, Campylobacter, Eimeria

Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today issued the following letter to shareholders from its Chairman, President and Chief Executive Officer, John Payne.

Key Points: 
  • Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today issued the following letter to shareholders from its Chairman, President and Chief Executive Officer, John Payne.
  • Through establishing partnerships and scaling our manufacturing capacity, ZIVO is undergoing a transformation aimed at maximizing the value of our product portfolio for our customers, partners, and shareholders.
  • Through this letter Id like to provide an overview of why others find our product candidates to be so attractive.
  • On behalf of the ZIVO team, as well as our Board of Directors, I want to thank our shareholders for their continued support.

ZIVO Reports that USDA Claims Regulatory Jurisdiction for New Coccidiosis Treatment

Retrieved on: 
Wednesday, August 10, 2022
Health, Infectious Diseases, Agriculture, Natural Resources, Pharmaceutical, Biotechnology, Veterinary, Coccidiosis, Digestion, U.S. Securities and Exchange Commission, Drug Quality and Security Act, Poultry, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Face, Drug resistance, Growth, Securities Exchange Act of 1934, Center for Veterinary Medicine, Disease, MOA, Security (finance), Research, Parasitic disease, Bird, Letter, USDA, Center, Licensure, CVB, NASDAQ, Veterinary biologic, Securities Act of 1933, Chicken, Veterinary medicine, Health, Vaccine

The global poultry industry spends more than $1.5 billion annually on coccidiosis control, primarily using decades-old compounds that face growing anticoccidial drug resistance.

Key Points: 
  • The global poultry industry spends more than $1.5 billion annually on coccidiosis control, primarily using decades-old compounds that face growing anticoccidial drug resistance.
  • Coccidiosis is a common disease for chickens, especially among young chicks, and can be fatal or result in compromised digestion.
  • Im delighted with todays announcement that demonstrates ZIVOs commitment to advancing our product candidate toward commercialization and provides regulatory clarity.
  • With regulatory jurisdiction now confirmed, we will advance discussions with the CVB on the final product development plan, regulatory strategy and data requirements for licensure.

Torigen Expands Histopathology Services Through Strategic Partnership with Vidium Animal Health

Retrieved on: 
Wednesday, April 27, 2022
Emerald, Veterinary biologic, CEO, University of Notre Dame, CFR, Veterinarian, University of Connecticut, DVM, Pathology, Twitter, Lists of diseases, University, Research, Genomics, Translational Genomics Research Institute, Immunotherapy, Practitioner, TGEN, Patient, Cell, LinkedIn, Neoplasm, Growth, Infection, Efficiency, Cat, Antigen, Immune system, Health, Veterinary medicine, City, Radiation, PETS, Animal, Instagram, Diabetes, Notre Dame, Physician, Partnership, Disease, Horse, City of Hope, Precision medicine, Therapy, Cancer, Dog, Vaccine, Medical imaging, Pharmaceutical industry, Diagnosis, Facebook

FARMINGTON, Conn., April 27, 2022 /PRNewswire-PRWeb/ -- Torigen Pharmaceuticals, Inc, a commercial-stage animal health biologics company, today announced it has entered into a strategic partnership with Vidium Animal Health® to offer veterinarians a full spectrum of services from diagnosis to treatment. Vidium Animal Health combines extensive expertise in veterinary cancer pathology with genomic diagnostic testing to bring unparalleled advanced cancer diagnostics to veterinary medicine.

Key Points: 
  • FARMINGTON, Conn., April 27, 2022 /PRNewswire-PRWeb/ -- Torigen Pharmaceuticals, Inc, a commercial-stage animal health biologics company, today announced it has entered into a strategic partnership with Vidium Animal Health to offer veterinarians a full spectrum of services from diagnosis to treatment.
  • Vidium Animal Health combines extensive expertise in veterinary cancer pathology with genomic diagnostic testing to bring unparalleled advanced cancer diagnostics to veterinary medicine.
  • "We are excited to offer Vidium's unparalleled cancer diagnostic services to our veterinary clients," said Ashley Kalinauskas, CEO and co-founder of Torigen Pharmaceuticals.
  • "Vidium is thrilled to have the opportunity to provide comprehensive specialty pathology services to Torigen's clients," said Derick Whitley, DVM, DACVP, Vidium Animal Health Vice President of Strategy, Innovation, and Diagnostics.